6238-12-6

Basic information

• Product Name: 7-methoxy-4-methylquinoline
• Synonyms: 7-methoxy-4-methylquinoline;7-Methoxylepidine
• CAS NO: 6238-12-6
• Molecular Formula: C11H11NO
• Molecular Weight: 173.21114
• Mol File: 6238-12-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 301.3 °C at 760 mmHg
• Flash Point: 110.5 °C
• Appearance: /
• Density: 1.102 g/cm³
• Refractive Index: 1.6168
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.97±0.27(Predicted)
• CAS DataBase Reference: 7-methoxy-4-methylquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-methoxy-4-methylquinoline(6238-12-6)
• EPA Substance Registry System: 7-methoxy-4-methylquinoline(6238-12-6)

Safety Data

• Hazardous Substances Data: 6238-12-6(Hazardous Substances Data)

Usage

General Description

7-methoxy-4-methylquinoline is a chemical compound that belongs to the quinoline class of molecules. It is composed of a quinoline ring with a methyl group at the 4-position and a methoxy group at the 7-position. 7-methoxy-4-methylquinoline is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and research compounds. It has been studied for its potential biological activities, including its anti-inflammatory and antioxidant properties. Additionally, 7-methoxy-4-methylquinoline is also used in organic synthesis and as a reagent in chemical reactions. Overall, this compound has a wide range of applications and is important in both the pharmaceutical and chemical industries.

Upstream product

• 1070879-27-4 4-bromo-7-methoxyquinoline 
• 594-27-4 tetramethylstannane 
• 536-90-3 m-Anisidine 
• 78-94-4 methyl vinyl ketone 
• 97892-67-6 2-chloro-7-methoxy-4-methylquinolin 
• 1122-62-9 2-acetylpyridine 
• 68500-37-8 4-chloro-7-methoxyquinoline 
• 40053-37-0 4-methyl-7-methoxy-2(1H)-quinolinone 

Relevant articles and documents

Synthesis and antileishmanial evaluation of thiazole orange analogs

Cyanine compounds have previously shown excellent in vitro and promising in vivo antileishmanial efficacy, but the potential toxicity of these agents is a concern. A series of 22 analogs of thiazole orange ((Z)-1-methyl-4-((3-methylbenzo[d]thiazol-2(3H)-ylidene)methyl)quinolin-1-ium salt), a commercial cyanine dye with antileishmanial activity, were synthesized in an effort to increase the selectivity of such compounds while maintaining efficacy. Cyanines possessing substitutions on the quinolinium ring system displayed potency against Leishmania donovani axenic amastigotes that differed little from the parent compound (IC50 12–42 nM), while ring disjunction analogs were both less potent and less toxic. Changes in DNA melting temperature were modest when synthetic oligonucleotides were incubated with selected analogs (ΔTm ≤ 5 °C), with ring disjunction analogs showing the least effect on this parameter. Despite the high antileishmanial potency of the target compounds, their toxicity and relatively flat SAR suggests that further information regarding the target(s) of these molecules is needed to aid their development as antileishmanials.

Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies

A series of 4-quinolylhydrazones was synthesized and tested in vitro against Mycobacterium tuberculosis. At a concentration of 6.25 μg/mL, most of the newly synthesized compounds displayed 100% inhibitory activity against M. tuberculosis in cellular assays. Further screening allowed the identification of very potent antitubercular agents. Compound 4c was also tested in a time-course experiment and against mtb clinical isolates, displaying interesting results.

Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.